Prostate Prescriptions may increase the risk of prostate cancer

FDA warning: 5-alpha reductase inhibitors. What is the best prostate formula and natural alternative for enlarged prostate symptoms?
Bookmark and Share
Irving, TX (prHWY.com) July 14, 2011 - North Hollywood, CA., July 12 / New safety information based on the FDA's review of two large clinical trials: "the Prostate Cancer Prevention Trial "(PCPT) and "Reduction by Dutasteride of Prostate Cancer Events (REDUCE)" trial. Both trials showed an increased incidence of high-grade prostate cancer with finasteride and dutasteride treatment. These medications are classified as 5-alpha reductase inhibitors (5-ARIs). Per the FDA "drugs in the 5-ARI class are finasteride and dutasteride. These drugs are marketed under the brand-names Proscar, Propecia, Avodart, and Jalyn."

How many men are at risk? Reports show that approximately 5 million men received a prescription for a 5-ARI between years 2002 and 2009. It is estimated that approximately 3 million of these patients were between 50 and 79 years of age.1

It is important to note that the increased risk of prostate cancer was reported with the more serious type of prostate cancer defined as: "GS 8-10 Prostate Cancers". It is suggested that risk for this form of "high-grade cancer" appears to be low. Obviously, for individuals that incurred this form of "high-grade cancer" the risk was too high.

It truly is becoming obvious that maybe some of these prescription medications are not as safe as we think they are. It is virtually impossible to turn on the television and not see a law firm commercial regarding this medication or that. This is why it is important to choose a health care provider that you trust and with whom you can discuss your health concerns.

Outside North America, physicians and health care professionals rely more heavily on natural products which we call dietary supplements to address health problems. This can be easily discerned from reviewing pharmaceutical revenues for a respective medication in comparison to revenue generated outside of North America. In addition, outside North America, the number of insurance carriers covering individuals and willing to pay for expensive prescription medications on a monthly basis is extremely limited or simply not available.

"Proscar, Avodart, and Jalyn are FDA approved 5-ARIs to improve symptoms of an enlarged prostate gland (benign prostatic hyperplasia or BPH). Proscar and Avodart are also FDA approved to reduce the risk of urinary retention or surgery related to an enlarged prostate."2 "Propecia is an FDA approved 5-ARI to treat male pattern hair loss."3

Outside North America, plant sterols or beta-sitosterol have been relied upon for the relief of BPH or the symptoms of an enlarged prostate for decades. There is no disputing that the symptoms of an enlarged prostate or BPH drastically affect daily living. Tens of thousands of men have discovered that the natural ingredient beta-sitosterol can actually address these symptoms without the side effects of prescription medications. For years the medical community recommended saw palmetto to address the symptoms of an enlarged prostate. However in 2006 a study published in the New England Journal of Medicine demonstrated that taking saw palmetto for an enlarged prostate was no more effective than a placebo. For men that want to try non-SOY, non-GMO derived beta-sitosterol for the symptoms of an enlarged prostate there is Best ProstateTM at
www.bestprostate.com or www.naturalprostateformula.com

Vector One®: Total Patient Tracker (TPT). Years 2002-2009. Data extracted 5-24-11.
www.fda.gov/Drugs/DrugSafety/ucm258314.htm

###

Tag Words: best prostate
Categories: Health

Press Release Contact
For information, contact:
Scottie Jack, CEO
IMS Supplements, Inc.
North Hollywood, CA 91603
888-768-3836
customerservice@imssupplements.com

Link To This Press Release:

URL HTML Code
Create Press Release
Press Release Options
About This Press Release
If you have any questions about this press release, please contact the listed publisher. Please do not contact prHWY as we cannot help you with your inquiry.